Publications by authors named "L Morantes"
: High-volume online hemodiafiltration (OL-HDF) has proven to be the most efficient dialysis modality and to offer better clinical outcomes in patients on hemodialysis. Longer and more frequent dialysis sessions have demonstrated clinical and survival benefits. : A single-center observational study of the first one hundred patients on nocturnal every-other-day OL-HDF was conducted with the aim of reporting the experience with this treatment schedule and evaluating analytical and clinical outcomes as well as the patient and technique survival.
View Article and Find Full Text PDFComparative Effects of Acetate- and Citrate-Based Dialysates on Dialysis Dose and Protein-Bound Uremic Toxins in Hemodiafiltration Patients: Exploring the Impact of Calcium and Magnesium Concentrations.
Toxins (Basel)
October 2024
Article Synopsis
- Modern hemodialysis typically uses acetate as a buffer, which has been associated with chronic inflammation, while citrate is being explored as a potential alternative for dialysate.
- This study compares the efficacy of acetate- and citrate-based dialysates in terms of dialysis efficiency and the removal of protein-bound uremic toxins in patients undergoing hemodiafiltration.
- Results showed no significant differences in overall dialysis doses or most toxin reduction, but lower calcium and magnesium citrate dialysates led to better clearance of p-cresyl sulfate, indicating a need for further research to optimize dialysate formulas.
Contrast-induced encephalopathy is a neurological complication related to contrast used in endovascular procedures or computed tomography (CT). The main risk factors are arterial hypertension, diabetes mellitus, chronic kidney disease (CKD), hyperosmolar contrasts, the amount of infused contrast and its direct infusion in the posterior cerebral territory, or pathologies with blood-brain barrier damage. Symptomatology is non-specific and may present as altered level of consciousness, neurological focality or seizures.
View Article and Find Full Text PDFArticle Synopsis
- C3 glomerulopathy is a rare kidney disease caused by issues with the alternative complement pathway, and current treatments vary based on severity but lack a specific approved solution.
- New potential treatments, like iptacopan (a factor B inhibitor), have shown promise in initial trials, particularly for recurrence after kidney transplants.
- Two real-world cases of C3 glomerulopathy recurrence treated with iptacopan demonstrated effective results and safety, suggesting that targeting the proximal complement pathway could be a viable treatment approach.
Background: The pretransplant diagnosis of liver malignancies in nodular cirrhotic livers remains a diagnostic challenge despite current advances. Although the prognostic impact of incidental hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (iCC) in liver transplant recipients is well documented, there are no data on the impact in simultaneous liver kidney transplant (LKT) recipients.
Methods: This is a single-center observational, retrospective study of all LKT performed from May 1993 to April 2022.